Group 1 - The core viewpoint of the news is that Sinovac Biotech's stock has experienced a decline of 5.01%, with its current share price at 40.38 CNY and a total market capitalization of 8.127 billion CNY [1] - Sinovac Biotech, established on August 22, 1997, specializes in the research, production, and sales of recombinant protein drugs and micro-ecological preparations, with 97.38% of its revenue coming from pharmaceutical products [1] - The trading volume for Sinovac Biotech reached 194 million CNY, with a turnover rate of 2.30% [1] Group 2 - Huatai Baoxing Fund holds a significant position in Sinovac Biotech, with its Huatai Baoxing Kelong A fund (009124) owning 21,000 shares, representing 1.59% of the fund's net value, making it the eighth-largest holding [2] - The Huatai Baoxing Kelong A fund was established on May 11, 2020, and has a current scale of 20.8067 million CNY, with a year-to-date return of 9.58% and a one-year return of 14.97% [2] - The fund manager, Zhou Yongmei, has a tenure of 7 years and 213 days, with a best return of 43.67% during her management period [3]

科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 3 3 | 17 | 日~2026 | 年 | 月 | 日 16 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 1,269,333股 | | | | | | | 累计已回购股数占总股本比例 | 0.63% | | | | | | | 累计已回购金额 | 4,738.19万元 | | | | | | | 实际回购价格区间 | 23.14元/股~43.50元/股 | | | | | | 一、回购股份的基 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company announced the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd [1][2] - "GB08 Injection" is the company's first independently developed Class I innovative drug, designed to address the needs of clinical patients with growth hormone deficiency in children, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of "GB08 Injection" in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine Affiliated Children's Hospital [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial of "GB08 Injection" is not expected to have a significant impact on the company's recent financial status or operating performance [3]

Group 1 - The company announced the successful enrollment of the first subject in the Phase II clinical trial of GB08 injection, which is an innovative drug developed for children with growth hormone deficiency [1][2] - GB08 injection is the company's first self-developed Class I innovative drug, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of GB08 injection in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine [2] Group 2 - The successful enrollment of the first subject in the clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [3]

Group 1 - The core point of the announcement is that Kexing Biopharmaceutical Co., Ltd. has successfully completed the enrollment of the first subject in the Phase II clinical trial of its self-developed GB08 injection, which is aimed at treating children with growth hormone deficiency [1][2] - GB08 injection is the company's first independently developed Class I innovative drug, designed as a long-acting growth hormone based on the needs of clinical patients [1][2] - The clinical trial for GB08 injection has received ethical approval from Zhejiang University School of Medicine Affiliated Children's Hospital, and the trial is a multi-center, randomized, open-label, positive-controlled Phase II/III study [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [2] - The company will continue to monitor the progress of the GB08 injection and fulfill its disclosure obligations in accordance with relevant regulations [2]

格隆汇9月2日丨科兴制药(688136.SH)公布，公司全资子公司深圳科兴药业有限公司（以下简称"深圳科 兴"）研发的"GB08注射液"II期临床研究成功完成首例受试者入组给药。公司子公司深圳科兴开展的临 床试验"评价GB08注射液治疗儿童生长激素缺乏症受试者的有效性和安全性的多中心、随机、开放、阳 性对照的II/III期临床研究"于2025年7月获得临床试验组长单位浙江大学医学院附属儿童医院的伦理批件 （批件号：2025-IEC-0009-P-01），并已于近日完成首例受试者入组给药。 GB08注射液是公司首个自主研发的I类创新药，是公司根据临床患者需求、基于儿童生长激素缺乏症而 自主研发的一款Fc融合蛋白长效化生长激素，公司GB08注射液按治疗用生物制品1类"创新型生物制 品"申报。 ...

公司通过DNA重组技术，将人生长激素（hGH）基因与IgG4亚型Fc段基因连接 后表达，形成具有同源二聚体蛋白结构的创新药物，显著提高了产品安全性及患 者的用药便利性和依从性，未来如成功研发上市将为儿童生长激素缺乏症患者带 来新的治疗手段。 二、"GB08注射液"研究进展情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-072 科兴生物制药股份有限公司 自愿披露关于 GB08 注射液 II 期临床试验 完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科 兴药业有限公司（以下简称"深圳科兴"）研发的"GB08注射液"II期临床研究 成功完成首例受试者入组给药。现将相关情况公告如下： 一、"GB08注射液"基本情况 GB08注射液是公司首个自主研发的I类创新药，是公司根据临床患者需求、 基于儿童生长激素缺乏症而自主研发的一款Fc融合蛋白长效化生长激素，公司 GB08注射液按治疗用生物制品1类"创新型生物制品"申报。 公 ...

Core Viewpoint - The announcement highlights the successful completion of the first patient enrollment and dosing in the Phase II clinical study of "GB08 Injection," an innovative drug developed by the company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd [1] Group 1: Product Development - GB08 Injection is the company's first independently developed Class I innovative drug targeting growth hormone deficiency in children [1] - The drug is based on the clinical needs of patients and utilizes DNA recombinant technology to connect the human growth hormone (hGH) gene with the IgG4 Fc segment gene, resulting in a novel drug with a homologous dimeric protein structure [1] - The innovative drug significantly enhances product safety, patient convenience, and adherence to treatment [1] Group 2: Market Potential - If successfully developed and launched, GB08 Injection will provide new treatment options for patients suffering from growth hormone deficiency in children [1]

Core Viewpoint - The announcement highlights the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by the company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. [1] Group 1 - The clinical trial aims to evaluate the efficacy and safety of GB08 Injection for treating children with growth hormone deficiency [1] - This trial is a multi-center, randomized, open-label, positive-controlled Phase II/III clinical study [1] - The ethical approval for the trial has been obtained recently, and the first subject has been enrolled and administered [1] Group 2 - The trial is not expected to have a significant impact on the company's recent financial status and operating performance [1]